Zimmer Biomet Holdings Inc (ZBH) : Litman Gregory Asset Management added new position in Zimmer Biomet Holdings Inc during the most recent quarter end. The investment management firm now holds 300 shares of Zimmer Biomet Holdings Inc which is valued at $35,232 , the company said in a statement filed on May 11, 2016 with the SEC.Zimmer Biomet Holdings Inc makes up approximately 0.03% of Litman Gregory Asset Management’s portfolio.
Other Hedge Funds, Including , United Capital Financial Advisers reduced its stake in ZBH by selling 1,595 shares or 5.31% in the most recent quarter. The Hedge Fund company now holds 28,440 shares of ZBH which is valued at $3.3 Million. Zimmer Biomet Holdings Inc makes up approx 0.04% of United Capital Financial Advisers’s portfolio.Manufacturers Life Insurance Company The boosted its stake in ZBH in the latest quarter, The investment management firm added 42,919 additional shares and now holds a total of 936,675 shares of Zimmer Biomet Holdings Inc which is valued at $110 Million. Zimmer Biomet Holdings Inc makes up approx 0.17% of Manufacturers Life Insurance Company The’s portfolio.Tdam Usa reduced its stake in ZBH by selling 3,465 shares or 4.49% in the most recent quarter. The Hedge Fund company now holds 73,733 shares of ZBH which is valued at $8.5 Million. Zimmer Biomet Holdings Inc makes up approx 0.42% of Tdam Usa’s portfolio. Harel Insurance Investments Financial Services Ltd. added ZBH to its portfolio by purchasing 170 company shares during the most recent quarter which is valued at $19,618.
Zimmer Biomet Holdings Inc opened for trading at $117.48 and hit $119.99 on the upside on Monday, eventually ending the session at $119.6, with a gain of 1.84% or 2.16 points. The heightened volatility saw the trading volume jump to 15,45,862 shares. Company has a market cap of $23,829 M.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.93. The company had revenue of $1904.00 million for the quarter, compared to analysts expectations of $1878.31 million. The company’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 135 from a previous price target of $130 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 132 from a previous price target of $120 .Zimmer Biomet Holdings Inc was Initiated by Nomura to “Buy” on Mar 17, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.